Abstract

Tumorigenic cells undergo cell aggregation and aggregate coalescence in a 3D Matrigel environment. Here, we expanded this 3D platform to assess the interactions of normal human dermal fibroblasts (NHDFs) and human primary mammary fibroblasts (HPMFs) with breast cancer-derived, tumorigenic cells (MDA-MB-231). Medium conditioned by MDA-MB-231 cells activates both types of fibroblasts, imbuing them with the capacity to accelerate the rate of aggregation and coalescence of MDA-MB-231 cells more than four fold. Acceleration is achieved 1) by direct physical interactions with MDA-MB-231 cells, in which activated fibroblasts penetrate the MDA-MB-231/Matrigel 3D environment and function as supporting scaffolds for MDA-MB-231 aggregation and coalescence, and 2) through the release of soluble accelerating factors, including matrix metalloproteinase (MMPs) and, in the case of activated NHDFs, SDF-1α/CXCL12. Fibroblast activation includes changes in morphology, motility, and gene expression. Podoplanin (PDPN) and fibroblast activation protein (FAP) are upregulated by more than nine-fold in activated NHDFs while activated HPMFs upregulate FAP, vimentin, desmin, platelet derived growth factor receptor A and S100A4. Overexpression of PDPN, but not FAP, in NHDF cells in the absence of MDA-MB-231-conditioned medium, activates NHDFs. These results reveal that complex reciprocal signaling between fibroblasts and cancer cells, coupled with their physical interactions, occurs in a highly coordinated fashion that orchestrates aggregation and coalescence, behaviors specific to cancer cells in a 3D environment. These in vitro interactions may reflect events involved in early tumorigenesis, particularly in cases of field cancerization, and may represent a new mechanism whereby cancer-associated fibroblasts (CAFs) promote tumor growth.

Highlights

  • It is well-established that stromal cells are hijacked by a developing tumor to generate a tumorspecific stroma that, in turn, promotes cancer progression and metastasis [1]

  • The activated fibroblasts, referred to here as cancer cell conditioned-normal human dermal fibroblasts (CC-NHDFs) or cancer cell conditioned-human primary mammary fibroblasts (CC-HPMFs), are imbued with the capacity to invade the 3D Matrigel environment where they accelerate the rate of MDA-MB-231 cell aggregation and aggregate coalescence. We found that this acceleration is mediated by 1) soluble factors released by activated fibroblasts and 2) by the dynamic participation of CC-NHDFs and CC-HPMFs, which function as scaffolds for MDA-MB-231 aggregation

  • To determine if treatment of fibroblasts with media conditioned by MDA-MB-231 cells altered the shape and motility of the fibroblasts, NHDF cells were treated with cancer cell conditioned or fibroblast cell conditioned media as described in the Methods

Read more

Summary

Methods

Normal human dermal fibroblasts (NHDFs) and Fibroblast Growth Medium containing 2% fetal calf serum (FGM), insulin (5μg/mL) and FGF-2 (1ng/mL) were obtained from PromoCell (http://www.promocell.com/) and cells were cultured as specified by the supplier. Human Primary Mammary Fibroblasts (HPMFs), HPMF growth media (HPMF-GM), the Fibroblast Medium Supplement Kit (FBS, hydrocortisone, L-glutamine, FGF and an antibiotic-antimycotic solution) and gelatin coating solution were obtained from Cell Biologics HPMF cells were cultured in HPMF-GM with the added supplements for 6–7 passages as specified by the supplier. MDA-MB-231 breast cancer cells were obtained from ATCC and cultured for 12–15 passages in MCF media. (Life Technologies, Carlsbad, CA) supplemented with 5% horse serum, human recombinant EGF, insulin, hydrocortisone and cholera toxin, all obtained from Sigma Aldrich (St. Louis, MO), and penicillin-streptomycin from Thermo -Fisher (Grand Island, NY) [21]. GFP tagged human dermal fibroblasts (NHDFs-GFP) were obtained from Angio-proteomie (www. angioproteomie.com) and cultured according to the supplier’s directions

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call